GlassScriptPhysician profile
Ronda D Bertus
NPI 1437100260
$1,953.03
in general payments reported to CMS, 2019-2025
26 companies · $1,420 in 2025
The $1,420 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $533 · 2025: $1,420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,953.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,953.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $315.32 | 2024-2025 | |
| Madrigal Pharmaceuticals | $267.00 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $198.34 | 2024-2025 | Xifaxan, Relistor, Plenvu |
| Lilly USA, LLC | $189.67 | 2025 | Mounjaro, Zepbound, Jardiance |
| Intercept Pharmaceuticals, INC. | $182.13 | 2024-2025 | |
| Amgen INC. | $137.40 | 2024 | Repatha |
| Aimmune Therapeutics, INC. | $72.96 | 2025 | Vowst |
| Gilead Sciences, INC. | $70.23 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $65.05 | 2024-2025 | Iqirvo |
| Genzyme Corporation | $47.74 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $47.41 | 2025 | Dupixent |
| Janssen Biotech, INC. | $46.95 | 2024-2025 | Tremfya |
| Phathom Pharmaceuticals, INC. | $33.75 | 2025 | Voquezna |
| Qol Medical, LLC | $32.57 | 2025 | Sucraid |
| Ironwood Pharmaceuticals, INC | $30.59 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $30.39 | 2025 | Airsupra |
| Novo Nordisk INC | $27.25 | 2024-2025 | Ozempic |
| Radius Health, INC. | $21.21 | 2025 | Tymlos |
| Sumitomo Pharma America, INC. | $21.19 | 2025 | Gemtesa |
| Pfizer INC. | $19.17 | 2025 | |
| Alnylam Pharmaceuticals INC. | $18.40 | 2024 | Onpattro |
| Dynavax Technologies Corporation | $18.35 | 2025 | Heplisav-B |
| Takeda Pharmaceuticals U.S.A., INC. | $16.07 | 2025 | Eohilia |
| Sanofi Pasteur INC. | $14.99 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.60 | 2025 | |
| Glaxosmithkline, LLC. | $14.30 | 2025 | Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronda Bertus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.